Navigation Links
Human Genome Sciences Reports Initial Results of Randomized Phase 2 Trial of HGS-ETR1 in Combination With Bortezomib in Advanced Multiple Myeloma
Date:9/2/2008

competition, the uncertainty of patent and intellectual property protection, the Company's dependence on key management and key suppliers, the uncertainty of regulation of products, the impact of future alliances or transactions and other risks described in the Company's filings with the Securities and Exchange Commission. In addition, the Company will continue to face risks related to animal and human testing, to the manufacture of ABthrax and to FDA concurrence that ABthrax meets the requirements of the ABthrax contract. If the Company is unable to meet the product requirements associated with the ABthrax contract, the U.S. government will not be required to reimburse the Company for the costs incurred or to purchase any ABthrax doses, and we will not receive any of the expected revenues relative to ABthrax. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. Human Genome Sciences undertakes no obligation to update or revise the information contained in this announcement whether as a result of new information, future events or circumstances or otherwise.


'/>"/>
SOURCE Human Genome Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Video: New Research Discovers Independent Brain Networks Control Human Walking
2. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
3. Enrollment Begins on Human PK Study for Medidur(TM) FA
4. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
5. Study Confirms Limited Human-To-Human Spread of Avian-Flu Virus in Indonesia in 2006
6. Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process
7. Peregrine Researchers Report Data Showing Bavituximabs Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease
8. Dr. Roger Kenneth Hershline PhD MD, CEO of Global Humanceuticals, Inc. Donates New HIV Drug
9. Study Shows Plasma-Derived Human Thrombin Equivalent to Bovine Thrombin in Achieving Hemostasis in Surgery
10. Tengion Launches Second Phase 2 Clinical Trial of Regenerated Human Organ
11. Flexible Medical Systems Raises $1.2M Seed Investment for Initial Human Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... LONDON , Sept. 18, 2014 /PRNewswire/ ... Competition for innovation, increasing clinical development costs, new ... the fast-changing environment are important factors driving industry ... clinical trial costs continue to rise due to ... Studies conducted by industry think tanks suggest each ...
(Date:9/18/2014)... -- Decision Resources Group finds that Regeneron,s Eylea, the most ... wet AMD, is equally likely to be covered on ... is the standard of care for wet AMD. Of ... not identify a clear clinical or economic advantage with ... be listed on tier 1 or 2 on Medicare ...
(Date:9/18/2014)... 18, 2014  Zacks.com announces the list of stocks ... Equity Research analysts discuss the latest news and events ... in the blog include the Avanir Pharmaceuticals (Nasdaq: AVNR ... - Free Report ), Orexigen (Nasdaq: OREX - ... Report ) and Gilead (Nasdaq: GILD - Free ...
Breaking Medicine Technology:Patient Recruitment in Asia Biotech and Pharma Companies 2Patient Recruitment in Asia Biotech and Pharma Companies 3Regeneron's Eylea and Genentech's Lucentis Are Equally Likely to be Covered on Commercial and Medicare Advantage Plans for Wet AMD 2Regeneron's Eylea and Genentech's Lucentis Are Equally Likely to be Covered on Commercial and Medicare Advantage Plans for Wet AMD 3The Zacks Analyst Blog Highlights: Avanir Pharmaceuticals, NPS Pharmaceuticals, Orexigen, Medivation and Gilead 2The Zacks Analyst Blog Highlights: Avanir Pharmaceuticals, NPS Pharmaceuticals, Orexigen, Medivation and Gilead 3The Zacks Analyst Blog Highlights: Avanir Pharmaceuticals, NPS Pharmaceuticals, Orexigen, Medivation and Gilead 4The Zacks Analyst Blog Highlights: Avanir Pharmaceuticals, NPS Pharmaceuticals, Orexigen, Medivation and Gilead 5The Zacks Analyst Blog Highlights: Avanir Pharmaceuticals, NPS Pharmaceuticals, Orexigen, Medivation and Gilead 6
... Calif., Nov. 8, 2011 ICU Medical, Inc. (NASDAQ: ... presented this past weekend at the 36th annual meeting ... Anaheim, CA has shown that the company,s ChemoClave® closed ... and patients safe from accidental exposure to hazardous drugs ...
... Nov. 8, 2011 Boston Scientific Corporation (NYSE: ... PLATINUM Long Lesion trial, demonstrating excellent outcomes for the ... patients with long coronary lesions.  Results were presented today ... in La Jolla, California, and Co-Principal Investigator of the ...
Cached Medicine Technology:Breaking Study: ICU Medical, Inc. ChemoClave® System Costs Less to Implement than any Closed System Transfer Device for the Safe Handling of Hazardous Drugs 2Breaking Study: ICU Medical, Inc. ChemoClave® System Costs Less to Implement than any Closed System Transfer Device for the Safe Handling of Hazardous Drugs 3Breaking Study: ICU Medical, Inc. ChemoClave® System Costs Less to Implement than any Closed System Transfer Device for the Safe Handling of Hazardous Drugs 4Boston Scientific's PROMUS Element™ Platinum Chromium Stent Demonstrates Excellent Outcomes in Patients With Long Coronary Lesions 2Boston Scientific's PROMUS Element™ Platinum Chromium Stent Demonstrates Excellent Outcomes in Patients With Long Coronary Lesions 3Boston Scientific's PROMUS Element™ Platinum Chromium Stent Demonstrates Excellent Outcomes in Patients With Long Coronary Lesions 4
(Date:9/19/2014)... September 19, 2014 A recent study ... that older patients with higher levels of vitamin D will ... includes more mobility, better ability to perform daily tasks, and ... at the University of Alberta’s School of Public Health. ... is vitally important to our bodies,” said Dr. Arash Bereliani, ...
(Date:9/19/2014)... Wisconsin (PRWEB) September 19, 2014 QueenBeeTickets.com has ... the Web. With a new tour set to begin on ... to be big sellers on the secure website. , ... for John Mellencamp’s tour at QueenBeeTickets.com. , The Plain Spoken ... all set to obtain seats for a show coming to ...
(Date:9/19/2014)... (PRWEB) September 19, 2014 Indiana Fiber ... Provider, announces the expansion of its Fiber Transport Services, ... in Chicago. By establishing a PoP at Cermak, ... Enterprise organizations looking for high bandwidth fiber transport service ... According to IFN Vice President of Sales and Marketing ...
(Date:9/19/2014)... Monroe, OH (PRWEB) September 19, 2014 ... Family YMCA to bring Health and Well-Being Coach Christi ... fitness career began after surviving brain tumors and gaining weight ... trainer, Hall began weight training and learning about nutrition. One ... and blood sugar, and increased her strength, endurance and cardio. ...
(Date:9/19/2014)... Va. (PRWEB) September 19, 2014 It isn’t ... Forest, a skilled nursing center that offers rehabilitation and assisted ... will this weekend when a young couple marries on site ... with their combined 140 years of marriage have helped showcase ... Sarah Horky, 18, and Dan Eads, 20, may have only ...
Breaking Medicine News(10 mins):Health News:Vitamin D Linked to Improved Quality of Life for Those over 50 2Health News:Vitamin D Linked to Improved Quality of Life for Those over 50 3Health News:John Mellencamp Plain Spoken Tour Tickets: QueenBeeTickets.com Delights Customers with Discount Tickets for Mellencamp’s 80-City 2015 Concert Tour with Carlene Carter 2Health News:Indiana Fiber Network Launches Point-Of-Presence in Chicago Data Center at Cermak 2Health News:Mount Pleasant Retirement Village Partners with Atrium Family YMCA 2Health News:Mount Pleasant Retirement Village Partners with Atrium Family YMCA 3Health News:Young Couple Inspired by Residents Of The Gardens At Warwick Forest To Wed There Saturday 2Health News:Young Couple Inspired by Residents Of The Gardens At Warwick Forest To Wed There Saturday 3
... Cholesterol-lowering meds seem to shield against troublesome complication, study ... patients who take cholesterol-lowering statins before cardiac surgery may ... study finds. , Depending on variables such as ... 47 percent of people experience this condition of confusion ...
... mechanics can lead to pain and stiffness , , THURSDAY, Dec. 25 ... back. , To ease the backaches that may have come ... and stretching and straining to put up holiday decorations -- and that ... Association offers a 10-step guide: , Zero ...
... these cells more closely mimic those of humans , , ... found a formula to capture indefinitely the basic embryonic ... cells. , If the findings hold up, scientists ... readily produced, genetically altered strains of rats. As humans ...
... conflicting news reports on the ongoing Baxter Heparin blood thinner controversy. ... of death among several patients, but the agency has also alleged ... patients. , ... Denver, CO (PRWEB) December 25, 2008 ...
... Weber Denture Liner kit is designed to answer questions often ... my loose denture fit better, give me more comfort and ... use of this new always-soft Weber Denture Liner. All ... fit better with this new (Patent Pending) invention. The Weber ...
... at risk for dementia, Parkinsons, researchers say , , WEDNESDAY, ... causes them to kick or cry out during deep sleep ... new Canadian study suggests. , "It,s basically a disorder where ... Dr. Ronald B. Postuma, of McGill University in Montreal. "When ...
Cached Medicine News:Health News:Tips to Ease an Aching Back 2Health News:Scientists May Isolate Stem Cells From Rats, Other Mammals 2Health News:LegalView Updates its Baxter Heparin Information Portal with Conflicting News Reports on the Possible Dangers 2Health News:LegalView Updates its Baxter Heparin Information Portal with Conflicting News Reports on the Possible Dangers 3Health News:LegalView Updates its Baxter Heparin Information Portal with Conflicting News Reports on the Possible Dangers 4Health News:New Product Makes Loose Dentures Fit Better 2Health News:New Product Makes Loose Dentures Fit Better 3Health News:Sleep Disorder Could Signal Neurological Disease 2
Lyphochek Hemoglobin A2 Control is a human whole blood based product designed to monitor the performance of automated and manual procedures for the measurement of hemoglobin variants, including Hemog...
Liquichek Hematology Control (A) is an assayed hematology control for evaluating the performance of Abbott Cell-Dyn 1600, 1700, 3000, 3500 and 3700 analyzers with 5-part differential technology....
... Control is a bilevel liquid ... performance of the most widely ... A weak positive and a ... monitor the performance of your ...
Liquichek™ Ethanol/Ammonia Control is a liquid product used to monitor ethanol and ammonia test procedures in the clinical laboratory....
Medicine Products: